HYPERHOMOCYSTEINEMIA AND CARDIOVASCULAR DISEASES IN PATIENTS ON MAINTAINING DIALYSIS
https://doi.org/10.24884/1561-6274-2003-7-1-13-19
Abstract
Hyperhomocysteinemia and cardiovascular diseases in patients on maintaining dialysis.
About the Authors
V. A. DobronravovRussian Federation
A. A. Zhloba
Russian Federation
R. V. Golubev
Russian Federation
References
1. Bostom AG, Lathrop L Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 1997; 52 (1): 10-20
2. Buccianti G, Raselli S, Baragetti I et al. 5-methyltetrahydrofolate restores endothelial function in uraemic patients on convective haemodialysis. Nephrol Dial Transplant 2002; 17(5): 857-864
3. van Güldener С, Stam F, Stehouver CDA Homocysteine metabolism in renal failure. Kidneylnt 2001; 59 [Suppl. 78]: 234-237
4. Guttormsen AB, Ueland PM, Svarstad E, Refsum H Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure. Kidney Int 1997; 52 (2): 495-502
5. Khan IN, Protesi A, Yiannakis E et al. Homocysteinaemia in patients receiving renal replacement therapy (RRT): relationship with dietary nutrient intake and mode of RRT. Nephrol Dial Transplant 1997; 12 (11): 2470-2471
6. Fowler B The folate cycle and disease in humans. Kidney Int 2001; 59 [Suppl. 78]: 221-229
7. van Güldener С, Kulik W, Berger R et al. Homocysteine and methionine metabolism in ESRD: a stable isotope study. Kidneylnt 1999; 56(3): 1064-1071
8. Loehrer FMT, Angst CP, Brunner FP et al. Evidence for disturbed S-adenosylmethionine:S-adenosyIhomocysteine ratio in patients with ESRF: a cause for disturbed methylation reactions? Nephrol Dial Transplant 1998; 13 (3): 656-661
9. McCuIIy K S Homocysteine, folate,vitamin B6, and cardiovascular disease. JAMA 1998; 279 (5): 392-393
10. Perna AF, Ingrosso D, De Santo NG et al. Mechanism of erythrocyte accumulation of methylation inhibitor S-adenosylhomocysteine in uremia. Kidneylnt 1995; 47(1): 247-253
11. Ross R The pathogenesis of atherosclerosis. In: Braunwald E (ed.) Heart disease. A textbook of cardiovascular medicine. 4th ed. Philadelphia: W. B. Saunders Company; 1992: 1106-1125
12. Goldsmith DJA1 Covic A Coronary artery disease in uremia: etiology, diagnosis and therapy. Kidney Int 2001; 60 (6): 2059-2075
13. Perna AF, Ingrosso D, Castaldo P et al. Homocysteine and transmethylations in uremia. Kidney Int 2001; 59 [Suppl. 78]: 230-233
14. Boushey CJ, Beresford SAA1 Omenn GS, MotuIsky AG A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995; 274 (13): 1049-1057
15. Stangl V1 Baumann G, Stangl K Coronary atherogenic risk factors in women. Eu rHeart J 2002; 23 (22): 1738-1752
16. Nygard 0, Vollset SE, Refsum H et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 1995; 274 (16): 1526-1533
17. O CaIIaghan P, Meleady R, Fitzgerald T, Graham I Smoking and plasma homocysteine. Eur Heart J 2002; 23 (20): 1580-1586
18. Wilcken DEL Homocysteine, smoking and vascular disease. Eur Heart J 2002; 23 (20): 1559-1560
19. Kunz K, Petitjean P, Lisri M et al. Cardiovascular morbidity and endothelial dysfunction in chronic HD patients: is homocysteine the missing link? Nephrol Dial Transplant 1999; 14(8): 1934-1942
20. Коношкова РЛ Ишемические изменения миокарда у больных с хронической почечной недостаточностью, получающих терапию гемодиализом. Нефрология 2000; 3: 18-26
21. Rosenthal AF, Ginsberg MJ, Crawford JF Homocysteine and heart disease in dialysis patients. Dial Transpl 1998; 27 (10): 627-630
22. Hagen W, Fodinger M, Heinz G et al. Effect of MTHFR genotypes and hyperhomocysteinemia on patient and graft survival in kidney transplant recipients. Kidney Int 2001; 59 [Suppl 78]: 253-257
23. DuclouxD, RuedinC, GibeyRetaI. Prevalence, determinants, and clinical significance of hyperhomocyst(e)inaemia in renal-transplant recipients. Nephrol Dial Transplant 1998; 13 (11): 2890-2893
24. Chauveau P, Chadefaux B1 Coude M et al. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int 1993; 43 [Suppl 41]: 72-77
25. Bergstrom J, Furst P Uraemic toxins. In: Drukker W1 Parsons FM, Maher JF (eds.) Replacement of renal function by dialysis. 2nd ed. Boston: Martinus Nijhoff publishers; 1984: 354-391
26. Libetta C, Villa G, Pirrelli S et al. Homocysteine plasma levels correlate with intimal carotid artery thickness in hemodialysis patients. Nephrol Dial Transplant 2001; 16 (12): 2444-2445
27. Sirrs S, Duncan L, Djurdjev O et al. Homocysteine and vascular access complications in hemodialysis patients: insights into a complex metabolic relationships. Nephrol Dial Transplant 1999; 14 (3): 738-743
28. Bostom AG, Shemin D1 Gohn RY et al. Treatment of hyperhomocysteinemia in hemodialysis patients and renal transplant recipients. Kidney Int 2001; 59 [Suppl 78]: 246-252
29. Stein G, Muller A, Busch M et al. Homocysteine, its metabolites, and В-group vitamins in renal transplant patients. Kidneylnt 2001; 59 [Suppl 78]: 262-265
30. Wrone EM, Zehnder JL1 Hornberger JM et al. An MTHFR variant, homocysteine and cardiovascular comorbidity in renal disease. Kidney Int 2001; 60 (3): 1106-1114
31. Fodinger M, Mannhalter C, Wolfl G et al. Mutation (677 C to T) in the methyltetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int 1997; 52 (2): 517-523
32. van Güldener С, Donker AJM1 Jakobs C et al. No net renal extraction of homocysteine in fasting humans. Kidney Int 1998; 54(1): 166-169
33. Ignnatescu MC, Fodinger M, Kletzmayr J et al. Is there a role of cyclosporine A on total homocysteine export from human renal proximal tubular epithelial cells? Kidneyint 2001; 59 [Suppl 78]: 258-261
34. Bostom AG, Shemin D, Lapane KL et al. High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidneylnt 1996; 49 (1): 147-1521
35. Ducloux D, Aboubakr A, Motte G et al. Hyperhomocysteinaemia therapy in hemodialysis patients: folinic vs folic acid in combination with vitamins B6 and Bt2 Nephrol Dial Transplant 2002; 17 (5): 865-870
36. van Güldener С, Janssen MJFM, Lambert J et al. No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients. Nephrol Dial Transplant 1998; 13 (1): 106-112
37. Rimm EB1 Willett WC1 Hu FB et al. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 1998; 279 (5): 359-365
38. Fodinger M1 Wagner OF1 Horl WH1 Sunder-Plassmann G Recent insights into the molecular genetics of the homocysteine metabolism. Kidney Int 2001; 59 [Suppl 78]: 238-242
39. Liangos 0, Kreutz R, Beige J et al. Methylenetetrahydrofolate-reductase gene C677T variant and kidney-transplant survival. Nephrol Dial Transplant 1998; 13 (9): 2351-2354
40. Jacques PF; Bostom AG, Williams RR et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996; 93(1): 7-9
41. Massy ZA Reversal of hyperhomocyst(e)inaemia in chronic renal failure -is folic or folinic acid the answer? Nephrol Dial Transplant 1999; 14 (12): 2810-2812
42. Bayes B, Pastor MC, Bonal J et al. Homocysteine and lipid peroxidation in hemodialysis: role of folinic acid and vitamin E. Nephrol Dial Transplant 2001; 16 (11): 2172-2175
43. Mezzano D, Pais E, Aranda E et al. Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney Int 2001; 60 (5): 1844-1851
44. Massy ZA, Ceballos I, Chadefaux-Vekemens B et al. Homocyst(e)ine, oxidative stress, and endothelium function in uremic patients. Kidney Int 2001; 59 [Suppl 78]: 243-245
45. Arnadottir H, Berg A-L, Hegbrat J et al. Influence of haemodialysis on plasma total homocysteine concentration. Nephrol Dial Transplant 1999; 14 (1): 142-146
46. Churchill DN Comparative morbidity among hemodialysis and continuous ambulatory peritoneal dialysis patients. Kidney Int 1993; 43 [Suppl 41]: 16-22
47. Lameire N1VanhoIder RC, van Loo A et al. Cardiovascular diseases in peritoneal dialysis patients: The size of the problem. Kidneylnt 1996; 50 [Suppl 56]: 28-36
48. Vychytil A, Fodinger M, Wolfl G et al. Major determinants of hyperhomocysteinemia in peritoneal dialysis patients. Kidney/r>M998; 53 (6): 1775-1782
49. Brulez HFH, van Güldener С, Donker AJM, ter Wee PM The impact of an amino acid-based peritoneal dialysis fluid on plasma total homocysteine levels, lipid profile and body fat mass. Nephrol Dial Transplant 1999; 14 (1): 154-159
Review
For citations:
Dobronravov V.A., Zhloba A.A., Golubev R.V. HYPERHOMOCYSTEINEMIA AND CARDIOVASCULAR DISEASES IN PATIENTS ON MAINTAINING DIALYSIS. Nephrology (Saint-Petersburg). 2003;7(1):13-19. (In Russ.) https://doi.org/10.24884/1561-6274-2003-7-1-13-19